[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Rajalakshmi V, Chandran P, Selvambigai, Ganesh J: Metanephric stromal tumor: a novel pediatric renal neoplasm. Indian J Pathol Microbiol; 2009 Jul-Sep;52(3):389-91
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This tumor is usually centered in the renal medulla with a characteristic microscopic appearance which differentiates this lesion from congenital mesoblastic nephroma and clear cell sarcoma of the kidney.
  • The differentiation of metanephric stromal tumor from clear cell sarcoma of the kidney will spare the child from the ill effects of adjuvant chemotherapy.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / pathology. Stromal Cells / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Histocytochemistry. Humans. Infant, Newborn. Nephroma, Mesoblastic / diagnosis. Sarcoma, Clear Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19679970.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


2. Balaguer Guill J, Fernández Navarro JM, Cañete Nieto A, Muro Velilla MD, Hernández Martí M, Castel Sánchez V: [Renal tumors in infants aged less than 1 year]. An Pediatr (Barc); 2006 May;64(5):433-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tumores renales en niños menores de un año.
  • OBJECTIVE: To determine the frequency and distribution of primary renal tumors diagnosed in a pediatric oncology unit in children younger than 1 year and identify their clinical and histopathological characteristics, the treatment used, and outcomes.
  • The most prevalent tumor in this age group was Wilms' tumor (WT) in 15 patients, followed by mesoblastic nephroma (MN) in 9 patients and rhabdoid tumor in 1 patient.
  • The mean age at diagnosis of WT was 4.8 months (range: 1 day-11 months), with a median of 5.03 months.
  • The median age at diagnosis of MN was 1 day (range: 1 day-3 months).
  • Overall survival at 5 years was 0.67 (SE 0.12) for WT and 0.89 (SE 0.1) for MN, respectively, with a mean follow-up of 290 months.
  • The first-line therapy in these patients is surgery since this type of tumor shows little chemosensitivity and chemotherapy is poorly tolerated in infants.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756884.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


3. Jones C, Rodriguez-Pinilla M, Lambros M, Bax D, Messahel B, Vujanic GM, Reis-Filho JS, Pritchard-Jones K: c-KIT overexpression, without gene amplification and mutation, in paediatric renal tumours. J Clin Pathol; 2007 Nov;60(11):1226-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Immunohistochemistry without antigen retrieval for CD117 was carried out on tissue microarrays consisting of 274 Wilms' tumours, 13 clear cell sarcomas of the kidney (CCSK), 10 mesoblastic nephromas (MN), and 7 rhabdoid tumours of the kidney (RTK).
  • RESULTS: Only 8/200 (4.0%) Wilms' tumours exhibited any degree of moderate-strong KIT staining in any of their assessable cell types.
  • This small group of KIT-positive tumours had a shorter time to relapse (p = 0.0044, log-rank test).
  • CONCLUSIONS: KIT overexpression in rare in Wilms' tumours, although does appear to confer a worse prognosis, in particular for patients primarily treated with preoperative chemotherapy.
  • The potential of anti-KIT therapeutic strategies in the treatment of paediatric renal tumours appears to be limited.
  • [MeSH-minor] Antineoplastic Agents. Child. DNA Mutational Analysis. DNA, Neoplasm / genetics. Gene Amplification. Humans. In Situ Hybridization / methods. Neoadjuvant Therapy. Nephrectomy. Prognosis. Survival Analysis. Tissue Array Analysis / methods

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biochem Cell Biol. 1999 Oct;31(10):1037-51 [10582338.001]
  • [Cites] Cell Oncol. 2007;29(5):399-408 [17726262.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1692-703 [11896121.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):486-92 [11914627.001]
  • [Cites] Am J Clin Pathol. 2003 Mar;119(3):325-7 [12645332.001]
  • [Cites] Am J Clin Pathol. 2003 Mar;119(3):339-45 [12645334.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1293-9 [13679437.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):37-46 [14700607.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):468-73 [14752069.001]
  • [Cites] J Clin Pathol. 2004 May;57(5):463-6 [15113851.001]
  • [Cites] Cancer Res. 1992 Nov 15;52(22):6139-43 [1384954.001]
  • [Cites] Virchows Arch. 1994;424(2):135-41 [7514077.001]
  • [Cites] J Histochem Cytochem. 1994 Nov;42(11):1417-25 [7523489.001]
  • [Cites] Hum Pathol. 1998 May;29(5):498-504 [9596274.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):49-57 [15545668.001]
  • [Cites] Diagn Cytopathol. 2005 Oct;33(4):228-32 [16138375.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):7986-94 [16299227.001]
  • [Cites] Cell Oncol. 2005;27(5-6):319-26 [16373964.001]
  • [Cites] Lab Invest. 2006 Apr;86(4):398-408 [16446704.001]
  • [Cites] J Pathol. 2006 Sep;210(1):49-58 [16823893.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11148-55 [17145858.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):4-18 [10632483.001]
  • (PMID = 17965221.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 11886
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC2095465
  •  go-up   go-down


Advertisement
4. Furtwaengler R, Reinhard H, Leuschner I, Schenk JP, Goebel U, Claviez A, Kulozik A, Zoubek A, von Schweinitz D, Graf N, Gesellschaft fur Pädiatrische Onkologie und Hämatologie (GPOH) Nephroblastoma Study Group: Mesoblastic nephroma--a report from the Gesellschaft fur Pädiatrische Onkologie und Hämatologie (GPOH). Cancer; 2006 May 15;106(10):2275-83
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesoblastic nephroma--a report from the Gesellschaft fur Pädiatrische Onkologie und Hämatologie (GPOH).
  • BACKGROUND: Surgery alone is the appropriate first-line treatment for patients with mesoblastic nephroma (MN).
  • The median age at diagnosis was 18.5 days.
  • The median observation time was 4.2 years.
  • Five patients older than 6 months received preoperative chemotherapy.
  • After they underwent nephrectomy, 40 patients received no further treatment.
  • Patients with a cellular MN, patients with age 3 months or older, and patients with Stage III MN had lower EFS.
  • Three patients developed recurrent disease, and 2 of those patients died.
  • Further prospective studies will be needed to verify this finding and should help determine whether these patients may benefit from adjuvant therapy.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / therapy. Nephroma, Mesoblastic / diagnosis. Nephroma, Mesoblastic / therapy
  • [MeSH-minor] Age Factors. Biopsy, Needle. Chemotherapy, Adjuvant. Child. Child, Preschool. Cohort Studies. Female. Germany. Humans. Immunohistochemistry. Infant. Infant, Newborn. Logistic Models. Male. Neoplasm Staging. Nephrectomy / methods. Pediatrics. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Societies, Medical. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society
  • (PMID = 16596620.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Loeb DM, Hill DA, Dome JS: Complete response of recurrent cellular congenital mesoblastic nephroma to chemotherapy. J Pediatr Hematol Oncol; 2002 Aug-Sep;24(6):478-81
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of recurrent cellular congenital mesoblastic nephroma to chemotherapy.
  • Congenital mesoblastic nephroma (CMN) is usually cured by surgery.
  • The sensitivity of this tumor to chemotherapy is unknown.
  • The recent description of a t(12;15)(p13;q25) chromosomal translocation in both cellular CMN and congenital infantile fibrosarcoma suggests that these entities have a common pathogenesis, and that cellular CMN might respond to chemotherapy like congenital infantile fibrosarcoma does.
  • The authors describe three patients with recurrent cellular CMN who showed a complete response to chemotherapy.
  • Based on these patients and a review of the literature, the authors suggest that chemotherapy be considered as a part of the therapy for recurrent or unresectable cellular CMN.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nephroma, Mesoblastic / drug therapy


6. Little SE, Bax DA, Rodriguez-Pinilla M, Natrajan R, Messahel B, Pritchard-Jones K, Vujanic GM, Reis-Filho JS, Jones C: Multifaceted dysregulation of the epidermal growth factor receptor pathway in clear cell sarcoma of the kidney. Clin Cancer Res; 2007 Aug 1;13(15 Pt 1):4360-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase overexpressed in a variety of human malignancies, against which targeted therapies have shown efficacy in lung and brain tumors.
  • In identifying a striking predilection for certain tumor types, we further analyzed the clear cell sarcomas of the kidney (CCSK) for mutations in EGFR and PTEN.
  • In addition, 5 of 9 (55.6%) mesoblastic nephromas and 12 of 12 (100%) CCSKs were strongly immunoreactive for EGFR.
  • Identification of factors predictive of poor response to targeted therapy, including the drug resistance T790M mutation, may provide a rationale for upfront trials with irreversible inhibitors of EGFR in children with these tumors.
  • [MeSH-minor] Child, Preschool. Gene Amplification. Humans. Immunoenzyme Techniques. In Situ Hybridization. Infant. Mutation. Nephroma, Mesoblastic / metabolism. Nephroma, Mesoblastic / pathology. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism. Rhabdoid Tumor / metabolism. Rhabdoid Tumor / pathology. Tissue Array Analysis. Wilms Tumor / metabolism. Wilms Tumor / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646270.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


7. Chan KL, Tang MH, Tse HY, Tang RY, Lam HS, Lee CP, Tam PK: Factors affecting outcomes of prenatally-diagnosed tumours. Prenat Diagn; 2002 May;22(5):437-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Medical records of all fetuses referred to our institutions with antenatally-diagnosed tumours were reviewed for the type and location of the tumours, results of treatment and/or causes of death.
  • RESULTS: From January 1994 to May 2001, there were 15 fetuses with antenatally- diagnosed tumours: mesoblastic nephroma (MN) (n=2); neuroblastoma (NB) (n=2); cystic hygroma (CH) (n=3); intracranial germ cell tumour (IGCT) (n=2); sacrococcygeal teratoma (SCT) (n=3) and haemangioma (liver, n=2; limb, n=1).
  • One baby had cardiac failure resulting from a lower limb haemangioma and needed drug therapy.
  • All solid tumours (MN, NB, SCT) of the live births had no recurrence after surgery with or without adjuvant chemotherapy.
  • CONCLUSION: Prenatally-diagnosed tumours without any other associated abnormality cause morbidity and mortality because of their location and vascularity.
  • [MeSH-minor] Adult. Female. Gestational Age. Humans. Pregnancy. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 John Wiley & Sons, Ltd.
  • (PMID = 12001204.001).
  • [ISSN] 0197-3851
  • [Journal-full-title] Prenatal diagnosis
  • [ISO-abbreviation] Prenat. Diagn.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. López Almaraz R, Villafruela Alvarez C, Rodríguez Luis J, Doménech Martínez E: [Neonatal neoplasms: a single-centre experience]. An Pediatr (Barc); 2006 Dec;65(6):529-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Neoplasias neonatales: experiencia de un centro.
  • OBJECTIVES: To describe the neoplasms diagnosed and treated in newborns (</= 28 days of life) in the Hospital Universitario de Canarias and their association with congenital abnormalities and to evaluate prenatal diagnosis of these tumors.
  • The variables analyzed were the percentage of neonatal neoplasms among the total number of cancer cases in children aged less than 14 years, their incidence among all the newborns in our hospital, sex, year of diagnosis, age at clinical diagnosis, the presence or absence of prenatal diagnosis, type of tumor (histologic diagnosis), association with syndromes or other congenital anomalies, treatment, and long-term outcome.
  • Males accounted for 43.8 % and females for 56.2 %, with a mean age at diagnosis of 5.5 days (range 1-28 days).
  • Five neonates (31.2 %) had a prenatal diagnosis, 60 % of which were made in the last 7 years of the study period.
  • Histologic diagnoses were neuroblastoma (n = 5; 31.2 %), teratoma/ germ cell tumor (n = 4; 25 %), soft tissue sarcoma (one fibrosarcoma of the thigh and two hemangiopericytoma of the back and heart; 18.8 %), and one case each of mesoblastic nephroma, cerebral tumor (ependymoblastoma), melanoma (associated with giant congenital melanocytic nevi), and acute leukemia (associated with Down syndrome).
  • Treatment consisted of surgery alone (n = 10; 62.5 %) and surgery plus chemotherapy (n = 5; 31.2 %); one patient received no treatment.
  • In the last 7 years, the prenatal diagnosis of these entities has improved.
  • Most of the neoplasms responded to therapy, mainly surgery, and long-term outcome was favorable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] An Pediatr (Barc). 2007 Jul;67(1):85-6 [17663916.001]
  • (PMID = 17194321.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


9. Patel Y, Mitchell CD, Hitchcock RJ: Use of sarcoma-based chemotherapy in a case of congenital mesoblastic nephroma with liver metastases. Urology; 2003 Jun;61(6):1260
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of sarcoma-based chemotherapy in a case of congenital mesoblastic nephroma with liver metastases.
  • Congenital mesoblastic nephroma was originally considered to be a benign neoplasm.
  • We describe a patient with isolated metastasis to liver and review the management, together with evidence that it may be more appropriate to use a vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) regimen rather than Wilm's tumor-based regimens in those cases for which chemotherapy is indicated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / congenital. Kidney Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / secretion. Nephroma, Mesoblastic / drug therapy. Nephroma, Mesoblastic / secondary. Sarcoma / drug therapy


10. Schenk JP, Engelmann D, Zieger B, Semler O, Wühl E, Furtwängler R, Graf N, Tröger J: [Radiologic differentiation of rhabdoid tumor from Wilms' tumor and mesoblastic nephroma]. Urologe A; 2005 Feb;44(2):155-61
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiologic differentiation of rhabdoid tumor from Wilms' tumor and mesoblastic nephroma].
  • [Transliterated title] Bildgebende Differenzierung des Rhabdoidtumors vom Nephroblastom und mesoblastischen Nephrom.
  • Differentiation between rhabdoid tumor (RT) and mesoblastic nephroma (MN) and Wilms' tumor (WT) by imaging studies in babies and young children before histological confirmation is useful to start optimal treatment early.
  • Only if more signs are observed together in one case can a RT be presumed, which may indicate an early biopsy before chemotherapy.
  • [MeSH-major] Diagnostic Imaging. Kidney Neoplasms / diagnosis. Nephroma, Mesoblastic / diagnosis. Rhabdoid Tumor / diagnosis. Wilms Tumor / diagnosis
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Kidney / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Lymph Nodes / pathology. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Male. Neoplasm Staging. Observer Variation. Sensitivity and Specificity


11. Jones VS, Cohen RC: Atypical congenital mesoblastic nephroma presenting in the perinatal period. Pediatr Surg Int; 2007 Mar;23(3):205-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical congenital mesoblastic nephroma presenting in the perinatal period.
  • Congenital mesoblastic nephroma (CMN) is a rare tumour of infancy having an overall good prognosis.
  • The course was complicated by recurrence in the latter two and refractoriness to chemotherapy and death in one.
  • [MeSH-major] Kidney Neoplasms / congenital. Nephroma, Mesoblastic / congenital

  • Genetic Alliance. consumer health - Congenital Mesoblastic Nephroma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 2000;196(3):199-204 [10729925.001]
  • [Cites] Prenat Diagn. 2003 Nov;23 (11):927-31 [14634980.001]
  • [Cites] Int J Urol. 2004 Jan;11(1):50-2 [14678186.001]
  • [Cites] Urol Int. 1998;61(4):254-6 [10364762.001]
  • [Cites] Pediatr Surg Int. 2002 Mar;18(2-3):123-7 [11956777.001]
  • [Cites] J Pediatr Surg. 2004 Apr;39(4):522-5 [15065020.001]
  • [Cites] Pediatr Surg Int. 2003 Sep;19(7):509-19 [14523568.001]
  • [Cites] Pediatr Nephrol. 2002 Mar;17(3):187-9 [11956858.001]
  • [Cites] J Urol. 2005 Jan;173(1):186-9 [15592071.001]
  • [Cites] Med Pediatr Oncol. 2003 May;40(5):288-92 [12652616.001]
  • [Cites] Rofo. 2005 Oct;177(10):1373-9 [16170706.001]
  • [Cites] Pediatr Surg Int. 2003 Apr;19(1-2):109-11 [12721740.001]
  • [Cites] J Pediatr Surg. 1989 Jun;24(6):599-600 [2544716.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Mar;21(3):265-9 [9523204.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Aug-Sep;24(6):478-81 [12218597.001]
  • (PMID = 17093992.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Onder AM, Teomete U, Argani P, Toledano S, Zilleruelo G, Rodriguez MM: PRCC-TFE3 renal cell carcinoma in a boy with a history of contralateral mesoblastic nephroma. Pediatr Nephrol; 2006 Oct;21(10):1471-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PRCC-TFE3 renal cell carcinoma in a boy with a history of contralateral mesoblastic nephroma.
  • We report here a 9-year old African-American boy with a history of a right congenital mesoblastic nephroma treated with nephrectomy and followed by annual checkups.
  • After 9 years, he was diagnosed with a mass at the hilum of the left kidney during the work-up of new-onset hypertension.
  • A limited biopsy revealed densely hyalinized connective tissue that was initially interpreted to be a hyalinized contralateral mesoblastic nephroma.
  • The child received chemotherapy, but the mass continued to grow.
  • Chromosomal analysis disclosed a t(X;1)(p11.2;q21) translocation, which is known to result in a PRCC-TFE3 gene fusion.
  • The tumor showed nuclear labeling for TFE3 protein by immunohistochemistry, supporting the above diagnosis.
  • He has been on hemodialysis, is tumor free, and has not been receiving chemotherapy for 24 months.
  • This is the first report of a RCC as a second malignant neoplasm in a child treated for a congenital mesoblastic nephroma.
  • [MeSH-major] Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics. Carcinoma, Renal Cell / genetics. Cell Cycle Proteins / genetics. Kidney Neoplasms / genetics. Neoplasm Proteins / genetics. Neoplasms, Second Primary / genetics. Nephroma, Mesoblastic / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 2000;196(3):199-204 [10729925.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jun;143(2):93-9 [12781442.001]
  • [Cites] Pediatr Dev Pathol. 2005 Mar-Apr;8(2):168-80 [15747097.001]
  • [Cites] J Urol. 2001 Jun;165(6 Pt 1):2013-6; discussion 2016-7 [11371919.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):976-85 [14983493.001]
  • [Cites] J Pediatr Surg. 1996 Jan;31(1):183-6 [8632275.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Jan;65(1):1-6 [8431910.001]
  • [Cites] J Pediatr Surg. 2004 Apr;39(4):522-5 [15065020.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1553-66 [12459622.001]
  • [Cites] Cancer Genet Cytogenet. 1995 May;81(1):72-5 [7773963.001]
  • [Cites] Adv Anat Pathol. 2003 Sep;10(5):243-60 [12973047.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1117-32 [15316311.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2208-16 [9827727.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5046-8 [9823307.001]
  • [Cites] Nat Genet. 1994 May;7(1):85-90 [7915601.001]
  • [Cites] J Urol. 2001 Oct;166(4):1455-8 [11547111.001]
  • [Cites] J Urol. 1994 Dec;152(6 Pt 2):2221-6 [7966714.001]
  • [Cites] Am J Surg Pathol. 1999 Jul;23(7):772-80 [10403299.001]
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):530-5 [12560445.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1575-83 [15378495.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1983;399(1):1-9 [6298998.001]
  • [Cites] J Pediatr. 2000 Jun;136(6):749-53 [10839871.001]
  • [Cites] Am J Surg Pathol. 1999 Jul;23(7):795-802 [10403302.001]
  • [Cites] Pediatr Radiol. 2003 Aug;33(8):540-5 [12748834.001]
  • (PMID = 16807766.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Cell Cycle Proteins; 0 / Neoplasm Proteins; 0 / PRCC protein, human; 0 / TFE3 protein, human
  •  go-up   go-down


13. Bisceglia M, Carosi I, Vairo M, Zaffarano L, Bisceglia M, Creti G: Congenital mesoblastic nephroma: report of a Case with review of the most significant literature. Pathol Res Pract; 2000;196(3):199-204
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital mesoblastic nephroma: report of a Case with review of the most significant literature.
  • AIMS AND BACKGROUND: Congenital mesoblastic nephroma (CMN) is a rare pediatric tumor of the kidney with the highest peak of incidence during the first 3 postnatal months.
  • Two morphological subtypes are currently distinguished histologically: the classical or leiomyomatous type and the atypical or cellular type.
  • Mixed forms with a combination of the two patterns are also on record.
  • Opinions concerning post-surgical clinical management, especially in regard to adjuvant therapy, are not unanimous.
  • METHODS: A case of CMN, predominantly of the classical histological subtype diagnosed in a baby with a follow-up of 6 years, is herein presented.
  • Since the tumor showed a high mitotic index (one of the characteristics of the cellular subtype) and the perirenal fat was focally involved with the tumor, the possibility of giving adjuvant chemotherapy was considered.
  • Consequently no additional therapy was given.
  • Six years after surgery the patient is developing well and is free of disease.
  • CONCLUSIONS: CMN almost always pursues a benign clinical course if diagnosed under three months of age and if totally surgically excised independent of histological type.
  • Criteria for management of atypical cases are not unanimous in regard to the benefit of additional therapy after surgery.
  • [MeSH-major] Kidney Neoplasms / congenital. Nephroma, Mesoblastic / congenital
  • [MeSH-minor] Biomarkers, Tumor / analysis. DNA, Neoplasm / analysis. Diploidy. Female. Flow Cytometry. Humans. Immunohistochemistry. Infant, Newborn. Mitotic Index. Treatment Outcome

  • Genetic Alliance. consumer health - Congenital Mesoblastic Nephroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10729925.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Number-of-references] 73
  •  go-up   go-down


14. McCahon E, Sorensen PH, Davis JH, Rogers PC, Schultz KR: Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy. Med Pediatr Oncol; 2003 May;40(5):288-92
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy.
  • BACKGROUND: Recently, the ETV6-NTRK3 gene fusion has been identified in both infantile fibrosarcoma and cellular mesoblastic nephroma.
  • For both these tumors standard curative treatment has been primarily surgical with wide local excision.
  • PROCEDURE: This report discusses three infants with congenital tumors, two congenital fibrosarcomas, and one atypical congenital mesoblastic nephroma, not easily amenable to surgical intervention.
  • RESULTS: All three were treated with pre-operative chemotherapy with excellent responses negating the need for amputation in two patients.
  • In this group of patients pre-operative chemotherapy may abrogate the need for morbid surgical procedures.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. DNA-Binding Proteins / genetics. Fibrosarcoma / congenital. Kidney Neoplasms / congenital. Nephroma, Mesoblastic / congenital. Receptor, trkC / genetics. Repressor Proteins / genetics. Soft Tissue Neoplasms / congenital

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12652616.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / ETS translocation variant 6 protein; 0 / Genetic Markers; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins; EC 2.7.10.1 / Receptor, trkC
  •  go-up   go-down


15. Hadley GP, Govender D, Landers G: Malignant solid tumours in neonates: an African perspective. Pediatr Surg Int; 2002 Dec;18(8):653-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroblastoma (NB) was the commonest tumour seen (11), but the soft-tissue sarcomas were the dominant group (14).
  • Chemotherapy, despite appropriate dose reduction, had significant morbidity and mortality.
  • Stage I disease was associated with a good prognosis, whilst stage IV disease was uniformly fatal.
  • Stage IVs disease had only 50% early survival.
  • Patients with renal tumours, whether nephroblastoma or mesoblastic nephroma, did well.
  • [MeSH-minor] Female. Humans. Infant, Newborn. Male. Neoplasm Staging. South Africa / epidemiology. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12598957.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Collins A, Demarche M, Dresse MF, Forget P, Lombet J, Jamblin P, Florkin B, Hoyoux C: [Renal tumors in children. A single center study of 31 cases]. Rev Med Liege; 2009 Nov;64(11):552-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Les tumeurs rénales de l'enfant. Une etude monocentrique: a propos de 31 cas.
  • The mean age at diagnosis in our series was surprisingly higher than usually described: 25% of the patients were older than 8 years.
  • Moreover, a mesoblastic nephroma congenital kidney tumour--appeared in a 10 month old girl.
  • Our study shows that preoperative chemotherapy results in a less intensive treatment regimen conducting probably to less sequellae.
  • Event free survival and overall survival were respectively 87% and 94% at 10 years after diagnosis.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / therapy
  • [MeSH-minor] Abdominal Pain / etiology. Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Hematuria / etiology. Humans. Infant. Infant, Newborn. Male. Nephrectomy. Radiotherapy, Adjuvant. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20069968.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


17. Reinhard H, Semler O, Bürger D, Bode U, Flentje M, Göbel U, Gutjahr P, Leuschner I, Maass E, Niggli F, Scheel-Walter HG, Stöckle M, Thüroff JW, Tröger J, Weirich A, von Schweinitz D, Zoubek A, Graf N: Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor. Klin Padiatr; 2004 May-Jun;216(3):132-40
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
  • BACKGROUND: The treatment of Wilms Tumor is integrated into clinical trials since the 1970's.
  • In contrast to the National Wilms Tumor Study Group (NWTSG) the SIOP trials and studies largely focus on the issue of preoperative therapy to facilitate surgery of a shrunken tumor and to treat metastasis as early as possible.
  • PATIENTS AND METHODS: In the SIOP 93-01/GPOH trial and study 1 020 patients with a newly diagnosed renal tumor were registered.
  • 847 of them had a histological proven Wilms Tumor, of whom 637 were unilateral localized, and 173 tumors had an other histology [40 congenital mesoblastic nephroma (CMN), 51 clear cell sarcoma (CCSK), 24 rhabdoid tumor (RTK) and 58 other tumors].
  • Preoperative chemotherapy in benign tumors was given to 1.3 % of the patients.
  • The main objective of the trial was the randomized question, if the postoperative two drug chemotherapy for stage I in intermediate risk or anaplasia can be reduced from conventional 3 courses to an experimental 1 course without loss of efficacy.
  • RESULTS: 519 patients with unilateral nonmetastatic Wilms did receive preoperative chemotherapy.
  • Tumor volume was measured in 487 patients before and in 402 after preoperative chemotherapy.
  • Randomisation was done in 43.7 % for stage I patients and there was no difference in EFS for both treatment arms (90 versus 91 %).
  • The tumor volume after chemotherapy is a prognostic factor for intermediate risk tumors with the exception of epithelial and stromal predominant tumors.
  • These two subtypes often present as large tumors, they do not shrink during preoperative chemotherapy but they still have an excellent prognosis.
  • On the other hand the prognosis of patients with blastemal predominant subtype after preoperative chemotherapy is worse than in any other patient group of intermediate risk tumors.
  • There are less blastemal predominant tumors compared to primary surgery, but they are chemotherapeutic resistant selected by the preoperative chemotherapy.
  • The post-operative chemotherapy in stage I can be reduced to 4 weeks without worsening treatment outcome.
  • The reduction of the tumor volume could be identified as a helpful marker for stratification of post-operative treatment.
  • Post-chemotherapy blastemal predominant subtype of Wilms tumor has to be classified as high risk tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Neoadjuvant Therapy. Wilms Tumor / drug therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Nephrectomy. Nephroma, Mesoblastic / drug therapy. Nephroma, Mesoblastic / mortality. Nephroma, Mesoblastic / pathology. Nephroma, Mesoblastic / surgery. Prognosis. Rhabdoid Tumor / drug therapy. Rhabdoid Tumor / mortality. Rhabdoid Tumor / pathology. Rhabdoid Tumor / surgery. Sarcoma, Clear Cell / drug therapy. Sarcoma, Clear Cell / mortality. Sarcoma, Clear Cell / pathology. Sarcoma, Clear Cell / surgery

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15175957.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


18. Tuveson DA, Fletcher JA: Signal transduction pathways in sarcoma as targets for therapeutic intervention. Curr Opin Oncol; 2001 Jul;13(4):249-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signal transduction pathways in sarcoma as targets for therapeutic intervention.
  • A large group of these genes participate in signal transduction pathways and represent potential sites of disease intervention with targeted therapies.
  • This review will discuss five types of sarcoma that display aberrant tyrosine kinase pathway signaling: gastrointestinal stromal tumor, inflammatory myofibroblastic tumor, congenital fibrosarcoma and mesoblastic nephroma, dermatofibrosarcoma protuberans, and desmoplastic small round cell tumor; one sarcoma predisposition syndrome with specific dysregulation of the ras pathway--neurofibromatosis--will also be discussed.
  • [MeSH-major] Signal Transduction. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans. Protein-Tyrosine Kinases / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11429482.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 80
  •  go-up   go-down


19. Takamizawa S, Scott D, Wen J, Grundy P, Bishop W, Kimura K, Sandler A: The survivin:fas ratio in pediatric renal tumors. J Pediatr Surg; 2001 Jan;36(1):37-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study evaluates the expression of survivin, as well as the prognostic value of the survivin:fas ratio in various types and stages of pediatric renal tumors.
  • METHODS: Multiple apoptosis mRNA species were quantified by Rnase protection assay (RPA) in 32 pediatric renal tumors and adjacent normal kidney specimens before chemotherapy: Wilms' tumor (WT), n = 9; clear cell sarcoma (CCS), n = 4; rhabdoid tumor of the kidney (RTK), n = 5; mesoblastic nephroma (MN), n = 3 and normal kidney, n = 11.
  • Follow-up data were obtained on patient outcomes, and antiapoptotic to proapoptotic ratios were calculated and correlated with clinical recurrence of disease.
  • The mean survivin:fas ratio was significantly greater in the 10 tumors that went on to recur after treatment (4 RTK, 3 CCS, 3 WT), than in tumors not recurring (2.16+/-1.4 v 1.0+/-1.07; P =.01, Kruskal-Wallis test).
  • CONCLUSIONS: The survivin:fas mRNA ratio is of prognostic value in its ability to predict recurrent disease in children undergoing treatment for pediatric renal tumors.
  • In this series, a ratio of greater than 1.6 predicted recurrent disease with a high probability irrespective of clinical stage or pathologic type.
  • Determining the survivin:fas ratio may guide treatment, follow-up and counseling of patients with pediatric renal tumors.
  • [MeSH-minor] Apoptosis. Blotting, Western. Child. Humans. Immunoenzyme Techniques. Inhibitor of Apoptosis Proteins. Neoplasm Proteins. Neoplasm Recurrence, Local / diagnosis. Predictive Value of Tests. Prognosis. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11150435.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proteins; 0 / RNA, Messenger
  •  go-up   go-down


20. Skotnicka-Klonowicz G, Bagłaj M, Sawicz-Birkowska K, Balcerska A, Dembowska B, Szymik-Kantorowicz S, Madziara W: [Nephroblastoma in children aged less than 6 months at diagnosis]. Med Wieku Rozwoj; 2003 Jul-Sep;7(3):347-57
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nephroblastoma in children aged less than 6 months at diagnosis].
  • We present the results of treatment of kidney tumours in newborns and infants aged less than 6 months, in the years 1993-2000, from the Nephroblastoma Committee of the Polish Paediatric Group of Solid Tumours (PPGGL).
  • We have analysed the diagnostic and treatment results in the group of 31 children aged 0 to 6 months.
  • The accuracy of diagnosis based on imaging studies was 97%.
  • Only in one child the initial diagnosis of kidney tumour was not confirmed; cystic degeneration of kidney was finally established.
  • In 10 cases histopathology confirmed mesoblastic nephroma, in 19 cases nephroblastoma and in 2 cases sarcoma clarocellulare.
  • In 10 infants (32.2%) with nephroblastoma delayed surgery preceded by chemotherapy was performed.
  • Indications for initial preoperative chemotherapy comprised: tumour in a single kidney, tumour in a horseshoe kidney, preoperative diagnostic biopsy of the tumour and large tumour in neonates older than 3 months.
  • The tolerance of reduced chemotherapy by the infants was good. AS was 100%.
  • ESF for the 19 children registered for nephroblastoma between 1993 and 1996 for all stages of advancement and types of histology was 94.75%.
  • CONCLUSIONS:. 1) Mesoblastic nephroma and low risk nephroblastoma are the most common tumours in children within the first three years of life.
  • 2) The results of treatment of nephroblastoma in the youngest children (below 6 months of age) are the most favourable and represent world standards.3) Surgical complications in children operated primarily for nephroblastoma indicate the need of performing such operations in academic centres, specialised in newborn surgery.
  • 4) In infants with extensive kidney tumours older than 3 months, primarily considered as inoperative, individual induction chemotherapy should be taken into account.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / therapy. Wilms Tumor / diagnosis. Wilms Tumor / therapy
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Infant. Infant, Newborn. Male. Nephroma, Mesoblastic / diagnosis. Nephroma, Mesoblastic / therapy. Poland. Retrospective Studies. Sarcoma, Clear Cell / diagnosis. Sarcoma, Clear Cell / therapy. Survival Analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14963342.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


21. Shet T, Viswanathan S: The cytological diagnosis of paediatric renal tumours. J Clin Pathol; 2009 Nov;62(11):961-9
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cytological diagnosis of paediatric renal tumours.
  • Fine needle aspiration cytology (FNAC) is used for preoperative diagnosis of paediatric renal tumours, especially in centres where preoperative chemotherapy is advocated in Wilms' tumour.
  • This review focuses on salient cytological features in specific paediatric renal tumours, the approach to resolving a differential diagnosis and the role of ancillary methods in diagnosis of paediatric renal tumours.
  • Crucial differential diagnoses include distinguishing: Wilms' tumour from benign tumours in the kidney like multicystic nephroma or congenital mesoblastic nephroma; aggressive non-Wilms' tumours of kidney like rhabdoid tumour of kidney; and Wilms' tumour from other paediatric round cell sarcomas like neuroblastoma, non-Hodgkin lymphoma etc.
  • An approach based on classifying smears according to their cellular patterns as triphasic, round cell, spindle cell or epithelioid cell type assists in classifying paediatric renal tumours on cytology.
  • A checklist of common tumours in a particular age group, relevant clinical information, awareness of distinctive and overlapping cytological features, and appropriate use of immunocytochemistry with cytogenetics go a long way in ensuring an accurate cytological diagnosis.
  • Used judiciously, FNAC is as effective a tool as a core biopsy for preoperative diagnosis of paediatric renal tumours, and with experience a 92% accuracy rate can be achieved.
  • [MeSH-minor] Adolescent. Age Distribution. Biopsy, Fine-Needle / methods. Carcinoma, Renal Cell / pathology. Child. Child, Preschool. Diagnosis, Differential. Humans. Infant. Infant, Newborn. Nephroma, Mesoblastic / pathology. Rhabdoid Tumor / pathology. Sarcoma, Clear Cell / pathology. Sarcoma, Ewing / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19700411.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 36
  •  go-up   go-down


22. Powis M: Neonatal renal tumours. Early Hum Dev; 2010 Oct;86(10):607-12
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Presentation is usually as a flank mass or as a coincidental finding on either antenatal or postnatal ultrasound.
  • Mesoblastic nephroma is the most common tumour to be found at this age, but Wilms' tumour and other malignant and benign tumours occur.
  • Cross sectional imaging is useful to delineate the extent of the disease.
  • Given the low malignant potential of these tumours, treatment is by radical nephroureterctomy, except in cases with bilateral disease or syndromic patients with a high incidence of metachronous tumours.
  • Chemotherapy is rarely indicated.
  • Survival is generally excellent for all tumour types in this age group, the exception being malignant rhabdoid tumour of the kidney which may have metastases at presentation.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Nephroma, Mesoblastic / diagnosis. Wilms Tumor / diagnosis
  • [MeSH-minor] Anatomy, Cross-Sectional. Diagnosis, Differential. Genetic Predisposition to Disease. Humans. Imaging, Three-Dimensional. Infant, Newborn. Neuroblastoma / diagnosis. Practice Guidelines as Topic. Risk Factors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20888153.001).
  • [ISSN] 1872-6232
  • [Journal-full-title] Early human development
  • [ISO-abbreviation] Early Hum. Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  •  go-up   go-down


23. Ekinci S, Karnak I, Tanyel FC, Senocak ME, Kutluk T, Büyükpamukçu M, Büyükpamukçu N: Hepatic lobectomies in children: experience of a center in the light of changing management of malignant liver tumors. Pediatr Surg Int; 2006 Mar;22(3):228-32
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatic resection is the main treatment modality for hepatic tumors in childhood.
  • The aim of this study is to report our experience in hepatic lobectomy, which is relatively rare procedure in childhood.
  • Age, gender, diagnosis, physical examination findings, results of preoperative laboratory investigations, radiological examination, resectability criteria, preoperative biopsies, chemotherapies, radiotherapies, postoperative pathological results, incisions, operation technique, intraoperative transfusions, drains used, antibiotic prophylaxes, and intraoperative and postoperative complications were evaluated for all patients.
  • Out of 25 patients with hepatic tumor seven patients with hepatoblastoma and four patients with hepatocellular carcinoma were given 5.7 +/- 0.3 cycles of chemotherapy before the operation.
  • Pathological examination of resected tumors revealed hepatoblastoma (n=11), mesenchymal hamartoma (n = 5), hepatocellular carcinoma (n = 4), hemangioendothelioma (n=1), malignant mesenchymal tumor (n = 1), hemangioma (n = 1), cyst adenoma (n = 1), and metastasis of cellular mesoblastic nephroma (n = 1).
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Infant. Magnetic Resonance Imaging. Male. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pediatr Surg Int. 2006 Aug;22(8):695
  • [Cites] Eur Urol. 1997;32(2):194-7 [9286653.001]
  • [Cites] J Pediatr Surg. 1991 Nov;26(11):1326-30 [1812268.001]
  • [Cites] Br J Surg. 1995 Mar;82(3):386-91 [7796018.001]
  • [Cites] Ann Thorac Surg. 1991 May;51(5):717-21; discussion 721-2 [1850976.001]
  • [Cites] J Pediatr Surg. 1984 Oct;19(5):523-6 [6094781.001]
  • [Cites] Surg Gynecol Obstet. 1957 Sep;105(3):310-8 [13467662.001]
  • [Cites] J Surg Res. 1996 Feb 15;61(1):183-9 [8769964.001]
  • [Cites] Surgery. 1998 Apr;123(4):407-14 [9551066.001]
  • [Cites] Hum Pathol. 1983 Jun;14(6):512-37 [6303939.001]
  • [Cites] Chirurgie. 1986;112(5):337-42 [3608701.001]
  • [Cites] World J Surg. 1982 Jan;6(1):3-9 [7090393.001]
  • [Cites] J Pediatr Surg. 2000 Oct;35(10 ):1459-61 [11051151.001]
  • [Cites] World J Surg. 1997 Mar-Apr;21(3):330-42 [9015180.001]
  • [Cites] J Pediatr Surg. 1992 Aug;27(8):1080-3; discussion 1083-4 [1328586.001]
  • [Cites] AJR Am J Roentgenol. 1993 Sep;161(3):572-3 [8352107.001]
  • [Cites] J Pediatr Surg. 1992 Jul;27(7):912-5 [1322458.001]
  • [Cites] J Pediatr Surg. 2001 May;36(5):755-9 [11329582.001]
  • (PMID = 16395609.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


24. Miniati D, Gay AN, Parks KV, Naik-Mathuria BJ, Hicks J, Nuchtern JG, Cass DL, Olutoye OO: Imaging accuracy and incidence of Wilms' and non-Wilms' renal tumors in children. J Pediatr Surg; 2008 Jul;43(7):1301-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The nWT group included congenital mesoblastic nephroma (5), clear cell sarcoma (4), neuroblastoma (4), renal cell carcinoma (4), lymphoma (2), angiomyolipoma (2), teratoma (1), hemangioma (1), and renal epithelial tumor (1).
  • Sensitivity, specificity, positive predictive value, and negative predictive value for computed tomography (CT) determining a diagnosis of WT were 0.92, 0.55, 0.84, and 0.73, respectively.
  • The CT reports explicitly stated a potential diagnosis in 89% of cases, with a diagnostic accuracy of 82%.
  • These data have significant implications for parental counseling, surgical plan, and the choice of neoadjuvant chemotherapy and argue in favor of obtaining a tissue diagnosis before instituting therapy.
  • [MeSH-major] Kidney / pathology. Kidney Neoplasms / diagnosis. Wilms Tumor / diagnosis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18639686.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Tröbs RB, Hänsel M, Friedrich T, Bennek J: A 23-year experience with malignant renal tumors in infancy and childhood. Eur J Pediatr Surg; 2001 Apr;11(2):92-8
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A retrospective analysis of 77 children treated between 1974 and 1996 was undertaken to evaluate morbidity and the evolution of therapy.
  • Low-risk tumors occurred in 5 of 63 children (8%; mesoblastic nephroma 3, cystic partially diff.
  • According to the SIOP/GPOH protocol in 1989, the regimen was switched from primary surgery to preoperative chemotherapy without biopsy in 1989 (11 pats.).
  • In 3 patients preoperative diagnosis by means of imaging failed.
  • During preoperative chemotherapy a venous occlusive disease of the liver occurred in 2 patients.
  • Preoperative chemotherapy led to an impressive tumor shrinkage in the majority of patients.
  • In our experience, reduction of tumor volume due to preoperative chemotherapy facilitates tumor removal by surgery and may prevent tumor spillage and the deleterious effects of radiation in young children.
  • Surgery without delay is necessary if the diagnosis is unclear or the tumor fails to respond to preoperative chemotherapy.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11371043.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


26. Hadley GP, Mars M: Hypertension in a cohort of African children with renal tumours. Pediatr Surg Int; 2006 Mar;22(3):219-23
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific antihypertensive therapy was offered to 11 patients who had either neurological or cardiac complications of hypertension.
  • All other patients with Wilms' tumour had their blood pressure controlled by neoadjuvant chemotherapy.
  • Patients with mesoblastic nephroma were managed by primary surgery.
  • Patients with asymptomatic hypertension may be monitored as hypertension will resolve with neoadjuvant chemotherapy.
  • Those with compelling symptomatology will require additional hypertensive medication.
  • [MeSH-minor] Africa / epidemiology. Biopsy, Needle. Child. Child, Preschool. Humans. Incidence. Infant. Infant, Newborn. Renin / blood. Retrospective Studies. Risk Factors. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pediatr Hematol Oncol. 1992 Aug;14(3):273-5 [1324619.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Jan-Feb;22(1):78-80 [10695827.001]
  • [Cites] Am J Clin Oncol. 1993 Jun;16(3):201-5 [8393271.001]
  • [Cites] J Pediatr Surg. 1981 Feb;16(1):32-4 [6262473.001]
  • [Cites] J Pediatr Surg. 1972 Oct-Nov;7(5):573-6 [4343314.001]
  • [Cites] Med Pediatr Oncol. 1993;21(3):213-21 [8383282.001]
  • [Cites] Pediatr Cardiol. 1997 Jan-Feb;18(1):43-4 [8960492.001]
  • [Cites] J Pediatr Surg. 1987 Mar;22(3):278-80 [3031261.001]
  • [Cites] J Clin Pathol. 1984 Jul;37(7):738-42 [6086723.001]
  • [Cites] Indian Pediatr. 1991 Jul;28(7):811-2 [1666062.001]
  • [Cites] Med Pediatr Oncol. 1986;14(1):63-6 [3005817.001]
  • [Cites] J Pediatr Surg. 1989 Jun;24(6):599-600 [2544716.001]
  • [Cites] Nephrol Dial Transplant. 2005 Jan;20(1):231-4 [15328387.001]
  • [Cites] J Pediatr Surg. 1988 May;23(5):403-9 [2837560.001]
  • [Cites] Br J Urol. 1995 Aug;76(2):241-3 [7663919.001]
  • [Cites] J Pathol. 1996 Sep;180(1):71-3 [8943818.001]
  • [Cites] S Afr Med J. 1990 Jun 2;77(11):565-7 [2161132.001]
  • [Cites] AJR Am J Roentgenol. 1992 May;158(5):1161-2 [1314476.001]
  • (PMID = 16421703.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.4.23.15 / Renin
  •  go-up   go-down


27. Ravindra S, Kini U: Cytomorphology and morphometry of small round-cell tumors in the region of the kidney. Diagn Cytopathol; 2005 Apr;32(4):211-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small round-cell tumors (SRCTs), with malignant cell components measuring 10 m or less in diameter with scanty cytoplasm in alcohol-fixed smears, pose a diagnostic challenge at fine-needle aspiration cytology (FNAC), especially when they are situated in and around the kidney and need facilities such as electron microscopy, immunohistochemistry, tissue culture, and cytogenetics for their subtyping.
  • A precise cytodiagnosis of SRCTs is important because a definite diagnosis is mandatory in preoperative diagnostic workup for presurgical chemotherapy in these cases.
  • With this view in mind, an attempt has been made to diagnose SRCTs in the region of the kidney based on cytomorphology and morphometry alone so as to facilitate its diagnosis in a simple cytology laboratory of a developing country where facilities for auxiliary techniques are not easily available.
  • Twenty-one were diagnosed as Wilms' tumor (WT), 10 were diagnosed as neuroblastoma (NB), 3 were ganglioneuroblastoma (GNB), 1 was a cellular congenital mesoblastic nephroma (CMN), and 1 was an adrenocortical carcinoma (ACC).
  • The latter were appreciated only on retrospective analysis after histological confirmation.Thus, morphometry in correlation with cytology, clinical history, physical findings, and radiological data is helpful in guided FNA for a definite diagnosis of SRCT in the region of the kidney.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15754373.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Levie NS, de Kraker J, Bökkerink JP, Appel IM, Aronson DC: SIOP treatment guidelines for renal tumours in small infants: fact or fantasy? Eur J Surg Oncol; 2000 Sep;26(6):567-70
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SIOP treatment guidelines for renal tumours in small infants: fact or fantasy?
  • Patients aged 7-12 months have been pre-treated with chemotherapy before nephrectomy is performed.
  • METHODS: Retrospective analysis of 67 patients under 12 months of age (1969-1995) with a unilateral renal tumour at diagnosis was carried out.
  • Demographics, pathology, staging and treatment variables were analysed.
  • In group A there were five patients (19%) with congenital mesoblastic nephroma (CMN), out of which one was still-born and therefore received no treatment, and 21 patients with a unilateral Wilms>> tumour (WT).
  • The known excellent survival rate justifies a primary nephrectomy approach in the youngest age group, however, in cases of a large tumour, pre-operative chemotherapy in reduced doses may still be considered.
  • [MeSH-major] Guideline Adherence. Kidney Neoplasms / surgery. Nephrectomy. Nephroma, Mesoblastic / surgery. Wilms Tumor / surgery
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Infant. Infant, Newborn. Male. Neoplasm Staging. Practice Guidelines as Topic. Preoperative Care. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Harcourt Publishers Ltd.
  • (PMID = 11034807.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] ENGLAND
  •  go-up   go-down


29. Jenkner A, Camassei FD, Boldrini R, de Sio L, Ravà L, Bosman C, Boglino C, Donfrancesco A: 111 renal neoplasms of childhood: a clinicopathologic study. J Pediatr Surg; 2001 Oct;36(10):1522-7
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most patients were treated within the frame of 3 consecutive SIOP trials, which included preoperative chemotherapy as their main feature.
  • RESULTS: In 98 patients (88%), nephroblastoma was diagnosed, followed by 6 adult-type renal tumors, 3 cystic nephromas, 2 mesoblastic nephromas, and 2 clear cell sarcomas.
  • For nephroblastoma, a statistically significant correlation between grade and both disease-free survival rate and 5-year survival rate, and between stage and overall survival rate was shown.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Logistic Models. Male. Proportional Hazards Models. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11584401.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement